Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| Baxter International Inc. | Abbott Laboratories | Elevance Health Inc. | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||
| Current share price (P) | $48.08 | ||||||
| No. shares of common stock outstanding | 543,887,683 | ||||||
| Growth rate (g) | 13.33% | ||||||
| Earnings per share (EPS) | $1.78 | ||||||
| Next year expected EPS | $2.02 | ||||||
| Operating profit per share | $0.83 | ||||||
| Sales per share | $18.33 | ||||||
| Book value per share (BVPS) | $16.26 | ||||||
| Valuation Ratios (Price Multiples) | |||||||
| Price to earnings (P/E) | 27.01 | 26.55 | 15.11 | 50.28 | 23.44 | 28.19 | |
| Price to next year expected earnings | 23.84 | 24.62 | 13.51 | 44.09 | 23.12 | 25.11 | |
| Price-earnings-growth (PEG) | 2.03 | 3.39 | 1.28 | 3.58 | 17.11 | 2.30 | |
| Price to operating profit (P/OP) | 58.24 | 21.51 | 13.02 | 48.75 | 17.40 | 17.92 | |
| Price to sales (P/S) | 2.62 | 3.91 | 0.43 | 14.27 | 3.09 | 0.77 | |
| Price to book value (P/BV) | 2.96 | 3.32 | 1.95 | 8.06 | 2.27 | 3.61 | |
Based on: 10-K (reporting date: 2015-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).
An analysis of the valuation multiples from 2011 to 2015 reveals a period of relative stability in revenue-based valuation, contrasted by significant volatility in earnings and operating profit multiples toward the end of the period. The divergence between these metrics suggests a fundamental shift in the relationship between the market price and the company's underlying financial performance in 2015.
- Price to Earnings (P/E) Ratio
- The P/E ratio exhibited a general upward trajectory, rising from 14.26 in 2011 to a peak of 22.32 in 2015. A temporary contraction occurred in 2014, where the ratio fell to 14.92 from 18.71 in the prior year, before increasing sharply in the final year of the period. This indicates an increasing market premium attributed to each dollar of net income.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio remained relatively stable between 10.76 and 14.11 from 2011 through 2014. However, a substantial increase is observed in 2015, with the ratio surging to 48.11. This extreme spike suggests a significant decline in operating profit relative to the stock price, marking a sharp departure from the historical trend established in the preceding four years.
- Price to Sales (P/S) Ratio
- The P/S ratio demonstrated the highest level of stability among the analyzed metrics. After a slight increase to 2.56 in 2012, the ratio entered a gradual decline, ending at 2.17 in 2015. This consistency indicates that the market's valuation of the company relative to its top-line revenue remained largely unchanged throughout the period.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio fluctuated within a narrow range between 4.45 and 5.23 from 2011 to 2014. In 2015, a significant contraction occurred, with the ratio dropping to 2.44. This downward movement, occurring simultaneously with the increase in P/E and P/OP ratios, suggests a notable increase in the book value of equity or a decrease in the market's valuation of the company's assets relative to its price.
Overall, the data indicates that while sales-based valuation remained constant, the company experienced a decoupled valuation trend in 2015. The simultaneous spike in earnings and operating profit multiples and the sharp decline in the book value multiple suggest a period of significant financial transition or a realignment of investor expectations regarding the company's profitability and asset base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Price to Earnings (P/E)
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 547,871,849 | 542,581,466 | 543,187,695 | 545,928,648 | 560,346,203 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to Baxter (in millions) | 968) | 2,497) | 2,012) | 2,326) | 2,224) | |
| Earnings per share (EPS)2 | 1.77 | 4.60 | 3.70 | 4.26 | 3.97 | |
| Share price1, 3 | 39.43 | 68.67 | 69.29 | 66.42 | 56.59 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 22.32 | 14.92 | 18.71 | 15.59 | 14.26 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| Abbott Laboratories | — | — | — | — | — | |
| Elevance Health Inc. | — | — | — | — | — | |
| Intuitive Surgical Inc. | — | — | — | — | — | |
| Medtronic PLC | — | — | — | — | — | |
| UnitedHealth Group Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).
1 Data adjusted for splits and stock dividends.
2 2015 Calculation
EPS = Net income attributable to Baxter ÷ No. shares of common stock outstanding
= 968,000,000 ÷ 547,871,849 = 1.77
3 Closing price as at the filing date of Baxter International Inc. Annual Report.
4 2015 Calculation
P/E ratio = Share price ÷ EPS
= 39.43 ÷ 1.77 = 22.32
5 Click competitor name to see calculations.
An analysis of valuation multiples from 2011 to 2015 reveals a period of moderate stability followed by significant volatility in the final year of the observed period.
- Share Price Trends
- The share price experienced a steady upward trajectory from 2011 to 2013, peaking at 69.29 US$. After remaining relatively stagnant through 2014, a sharp contraction occurred in 2015, with the price falling to 39.43 US$.
- Earnings Per Share (EPS) Performance
- EPS fluctuated moderately between 2011 and 2014, reaching a period high of 4.60 US$ in 2014. A substantial decline was recorded in 2015, where earnings dropped to 1.77 US$, indicating a significant reduction in net profitability per share.
- Price-to-Earnings (P/E) Ratio Interpretation
- Between 2011 and 2014, the P/E ratio remained within a range of 14.26 to 18.71, suggesting a consistent market valuation relative to earnings. In 2015, the ratio rose to a peak of 22.32. This expansion occurred because the decrease in earnings per share was proportionally more severe than the decrease in the share price, thereby inflating the multiple despite the overall decline in both price and earnings.
The data indicates that while the market valuation remained relatively stable for the first four years, the 2015 fiscal year was characterized by a misalignment between price and earnings, resulting in the highest P/E ratio of the period during a time of significant value erosion.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Price to Operating Profit (P/OP)
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 547,871,849 | 542,581,466 | 543,187,695 | 545,928,648 | 560,346,203 | |
| Selected Financial Data (US$) | ||||||
| Operating income (in millions) | 449) | 2,707) | 2,668) | 2,821) | 2,946) | |
| Operating profit per share2 | 0.82 | 4.99 | 4.91 | 5.17 | 5.26 | |
| Share price1, 3 | 39.43 | 68.67 | 69.29 | 66.42 | 56.59 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 48.11 | 13.76 | 14.11 | 12.85 | 10.76 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| Abbott Laboratories | — | — | — | — | — | |
| Elevance Health Inc. | — | — | — | — | — | |
| Intuitive Surgical Inc. | — | — | — | — | — | |
| Medtronic PLC | — | — | — | — | — | |
| UnitedHealth Group Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).
1 Data adjusted for splits and stock dividends.
2 2015 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 449,000,000 ÷ 547,871,849 = 0.82
3 Closing price as at the filing date of Baxter International Inc. Annual Report.
4 2015 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 39.43 ÷ 0.82 = 48.11
5 Click competitor name to see calculations.
Between 2011 and 2015, the relationship between market valuation and operating performance underwent a significant transformation. While the first four years exhibited a gradual expansion in valuation multiples, the final year saw an abrupt and severe divergence between the share price and underlying operating profitability.
- Share Price and Operating Profit Performance
- The share price experienced steady growth from US$ 56.59 in 2011 to a peak of US$ 69.29 in 2013, followed by relative stability in 2014 and a sharp decline to US$ 39.43 by the end of 2015. During the same period, operating profit per share remained relatively consistent from 2011 to 2014, fluctuating within a narrow range between US$ 4.91 and US$ 5.26. However, 2015 marked a critical inflection point, where operating profit per share plummeted to US$ 0.82.
- Price to Operating Profit (P/OP) Trend
- The P/OP ratio demonstrated a moderate upward trajectory from 2011 to 2013, increasing from 10.76 to 14.11, which indicates a rising market premium attributed to the company's operating earnings. After remaining stable at 13.76 in 2014, the ratio spiked to 48.11 in 2015, representing a nearly 250% increase in the multiple within a single year.
- Analysis of the 2015 Valuation Anomaly
- The exponential increase in the P/OP ratio in 2015 is the result of a disproportionate collapse in operating profit relative to the decline in share price. While the share price fell by approximately 42.6% from 2014 to 2015, the operating profit per share contracted by approximately 83.6%. Because the denominator decreased much more rapidly than the numerator, the resulting ratio of 48.11 suggests a severe misalignment between current operating earnings and the market valuation, typically indicative of a significant non-recurring operational shock or a structural transition.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Price to Sales (P/S)
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 547,871,849 | 542,581,466 | 543,187,695 | 545,928,648 | 560,346,203 | |
| Selected Financial Data (US$) | ||||||
| Net sales (in millions) | 9,968) | 16,671) | 15,259) | 14,190) | 13,893) | |
| Sales per share2 | 18.19 | 30.73 | 28.09 | 25.99 | 24.79 | |
| Share price1, 3 | 39.43 | 68.67 | 69.29 | 66.42 | 56.59 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 2.17 | 2.23 | 2.47 | 2.56 | 2.28 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| Abbott Laboratories | — | — | — | — | — | |
| Elevance Health Inc. | — | — | — | — | — | |
| Intuitive Surgical Inc. | — | — | — | — | — | |
| Medtronic PLC | — | — | — | — | — | |
| UnitedHealth Group Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).
1 Data adjusted for splits and stock dividends.
2 2015 Calculation
Sales per share = Net sales ÷ No. shares of common stock outstanding
= 9,968,000,000 ÷ 547,871,849 = 18.19
3 Closing price as at the filing date of Baxter International Inc. Annual Report.
4 2015 Calculation
P/S ratio = Share price ÷ Sales per share
= 39.43 ÷ 18.19 = 2.17
5 Click competitor name to see calculations.
The valuation metrics between 2011 and 2015 exhibit a period of moderate growth followed by a significant contraction in absolute values, while the relative price-to-sales valuation remained comparatively stable.
- Share Price Movement
- The share price experienced a steady ascent from 56.59 USD in 2011 to a peak of 69.29 USD in 2013. Following a period of relative stagnation in 2014, a sharp decline occurred in 2015, with the price falling to 39.43 USD.
- Sales per Share Performance
- A consistent upward trend in sales per share was observed from 2011 through 2014, rising from 24.79 USD to 30.73 USD. This growth trajectory was abruptly reversed in 2015, where sales per share contracted significantly to 18.19 USD.
- Price-to-Sales (P/S) Ratio Analysis
- The P/S ratio peaked in 2012 at 2.56, marking the highest valuation multiple of the analyzed period. From 2013 to 2015, a gradual downward trend is observed, concluding at 2.17. Notably, while both share price and sales per share plummeted in 2015, the P/S ratio only decreased slightly from 2.23 to 2.17. This indicates that the market valuation of the company's revenue remained relatively constant, as the decline in stock price was largely proportional to the decline in sales per share.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Price to Book Value (P/BV)
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 547,871,849 | 542,581,466 | 543,187,695 | 545,928,648 | 560,346,203 | |
| Selected Financial Data (US$) | ||||||
| Total Baxter shareholders’ equity (in millions) | 8,846) | 8,120) | 8,463) | 6,938) | 6,585) | |
| Book value per share (BVPS)2 | 16.15 | 14.97 | 15.58 | 12.71 | 11.75 | |
| Share price1, 3 | 39.43 | 68.67 | 69.29 | 66.42 | 56.59 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 2.44 | 4.59 | 4.45 | 5.23 | 4.82 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| Abbott Laboratories | — | — | — | — | — | |
| Elevance Health Inc. | — | — | — | — | — | |
| Intuitive Surgical Inc. | — | — | — | — | — | |
| Medtronic PLC | — | — | — | — | — | |
| UnitedHealth Group Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).
1 Data adjusted for splits and stock dividends.
2 2015 Calculation
BVPS = Total Baxter shareholders’ equity ÷ No. shares of common stock outstanding
= 8,846,000,000 ÷ 547,871,849 = 16.15
3 Closing price as at the filing date of Baxter International Inc. Annual Report.
4 2015 Calculation
P/BV ratio = Share price ÷ BVPS
= 39.43 ÷ 16.15 = 2.44
5 Click competitor name to see calculations.
The valuation metrics between 2011 and 2015 reveal a divergence between the company's intrinsic book value and its market valuation, culminating in a significant contraction during the final year of the period.
- Share Price Trends
- The share price experienced growth from 2011 to 2013, rising from US$56.59 to a peak of US$69.29. This valuation remained relatively stable through 2014 before undergoing a sharp decline to US$39.43 by December 31, 2015.
- Book Value Per Share (BVPS) Performance
- The book value per share exhibited a general upward trajectory over the five-year period. Starting at US$11.75 in 2011, the BVPS rose to US$16.15 by 2015, despite a marginal decrease observed in 2014. This suggests a consistent increase in the net asset value attributable to each share of common stock.
- Price to Book Value (P/BV) Analysis
- The P/BV ratio remained relatively stable from 2011 to 2014, fluctuating within a narrow range between 4.45 and 5.23. However, in 2015, the ratio dropped precipitously to 2.44. This decline was the result of a simultaneous peak in book value and a sharp contraction in share price, indicating a substantial reduction in the market premium that investors were willing to pay over the accounting value of the assets.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?